Alireza Atri, MD
Neurological Surgery · Boston, MANPI 1326038506
Payments from drug & device makers
Across 331 payments — averaging $5162.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$611K
- Eisai Inc.$583K
- Biogen$109K
- H. Lundbeck A S$93K
- Novo Nordisk$52K
- Novo Nordisk AS$52K
- plus $209K from 18 others
Across 5 payments — averaging $14,115 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$57K
- Novo Nordisk AS$14K
What the payments were for
- Consulting fees$333,86966%
- Speaking & faculty fees$108,72022%
- Travel & lodging$52,38210%
- Food & beverage$7,5722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 16 | $611,225 |
| Eisai Inc. | 105 | $582,701 |
| Biogen | 19 | $108,997 |
| H. Lundbeck A S | 17 | $93,135 |
| Novo Nordisk | 27 | $52,182 |
| Novo Nordisk AS | 15 | $51,996 |
| Novartis | 1 | $37,648 |
| AbbVie | 4 | $35,645 |
| Acadia Pharmaceuticals Inc | 19 | $31,568 |
| Grifols Shared Services North America, Inc. | 14 | $26,036 |
| Genentech USA, Inc. | 13 | $18,538 |
| Roche Products Limited | 5 | $13,073 |
| Lundbeck LLC | 13 | $11,911 |
| Merck | 15 | $8,617 |
| Axsome Therapeutics, Inc. | 6 | $8,232 |
| Biohaven Pharmaceuticals, Inc. | 2 | $5,942 |
| Genentech, Inc. | 2 | $5,200 |
| Otsuka America Pharmaceutical, Inc. | 24 | $2,473 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $2,000 |
| Grifols Biologicals LLC | 4 | $825 |
| Janssen Global Services, LLC | 6 | $778 |
| Life Molecular Imaging Ltd | 1 | $93 |
| F. Hoffmann-la Roche AG | 1 | $73 |
| Lilly USA, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$58,879
- Leqembi$40,089
- NUPLAZID$27,044
- Flebogamma DIF$25,400
- Albutein$20,803
- ADUHELM$12,559
- Non-Covered Product$7,069
- DISEASE EDUCATION$4,240
How this compares
$1,708,905 in reported general payments places this provider in the 95th percentile of 183 neurological surgery providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 12 | $249 |
Paid to pharmacies, not to this prescriber.
Other neurological surgery in Boston
- John ChiBoston$935K
- Simcha WellerBoston$905K
- Aman PatelBoston$832K
- Alexandra GolbyBoston$691K
- Robert RichardsonBoston$610K
- Peter WarnkeBoston$540K
- Philipp TausskyBoston$479K
- Garth CosgroveBoston$443K
- Benjamin RapoportBoston$419K
- Scellig StoneBoston$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.